报告期内，公司研发成果显著，陆续提交8项产品注册申请，4项接近完成注册前准备，获批3项新产 品，其中介入瓣中瓣、心包膜(ePTFE)为填补国产空白的产品。 报告期内，佰仁医疗充分发挥植入材料和器械创新平台的优势，多产品线在应对行业政策或竞争环境变 化时体现出了较强的韧性。与此同时，公司持续保持对管理费用和销售费用的有效控制，在一贯的高强 度研发投入情况下，公司归母净利润仍取得较高增长。 2月27日，北京佰仁医疗科技股份有限公司(以下简称"佰仁医疗")发布2025年业绩快报。报告期内，公 司实现营业总收入6.30亿元，同比增长25.60%；实现归母净利润2亿元，同比增长36.81%。 ...

2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载北京佰仁医疗科技股份有限公司（以下简称"公司"）2025年度主要财务数据为初步核算数 据，未经会计师事务所审计，具体数据以公司2025年年度报告中披露的数据为准，提请投资者注意投资 风险。 一、2025年度主要财务数据和指标 证券代码：688198 证券简称：佰仁医疗 公告编号：2026-001 北京佰仁医疗科技股份有限公司 单位：人民币万元 ■ 公司于2020年7月实施第二类限制性股票激励计划并首次授予了限制性股票，为便于投资者了解公司实 际经营的财务状况，将剔除股份支付影响的财务数据及指标列示如下： 单位：人民币万元 ■ 注：1、本报告期初数同法定披露的上年年末数。 2、以上财务数据及指标以合并报表数据填制，但未经审计，最终数据以公司2025年年度报告中披露的 数据为准。 3、以上数据及指标若有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 1、报告期内，公司充分发挥植入材料和器械创新平台的优势，多产品线在应对行业政策或竞争环境 ...

证券日报网讯 2月27日，佰仁医疗发布公告称，公司2025年度实现营业总收入63037.20万元，同比增长 25.60%；归属于母公司所有者的净利润20019.03万元，同比增长36.81%。 （文章来源：证券日报） ...

报告期内，公司持续保持对管理费用和销售费用的有效控制，在一贯的高强度研发投入情况下，实现归 属于母公司所有者的净利润20,019.03万元，同比增长36.81%。剔除股份支付影响后，本报告期归母扣 非后营业净利率为30.69%，符合公司预期。 格隆汇2月27日丨佰仁医疗(688198.SH)公布2025年度业绩快报，报告期内，公司充分发挥植入材料和器 械创新平台的优势，多产品线在应对行业政策或竞争环境变化时体现出了较强的韧性，本报告期延续自 2016年以来的持续快速增长势头，实现营业收入63,037.20万元，同比增长25.60%，其中结构性心脏病 板块同比增长26.07%，软组织修复板块同比增长24.23%。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载北京佰仁医疗科技股份有限公司（以下简称"公司"）2025年度主要财 务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年度报告中 披露的数据为准，提请投资者注意投资风险。 证券代码：688198 证券简称：佰仁医疗 公告编号：2026-001 北京佰仁医疗科技股份有限公司 2025年度业绩快报公告 一、2025年度主要财务数据和指标 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 63,037.20 | 50,187.91 | 25.60 | | 营业利润 | 22,336.88 | 15,322.02 | 45.78 | | 利润总额 | 21,750.62 | 15,078.62 | 44.25 | | 归属于母公司所有者的净利润 | 20,019.03 | 14,633.01 | 36.81 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | 1 ...

南财智讯2月27日电，佰仁医疗发布2025年度业绩快报，报告期内公司实现营业收入6.30亿元，同比增 长25.60%；归属于上市公司股东的净利润2.00亿元，同比增长36.81%；基本每股收益1.46元，同比增长 36.45%。 ...

Stock Performance - The closing price of Bairen Medical (688198.SH) on February 11, 2026, was 101.66 yuan, down 1.48%, with an intraday low of 101.11 yuan, marking a 60-day low [1] - The medical device sector declined by 0.48% on the same day, with a cumulative drop of 6.42% over the past 20 days, indicating weak overall industry sentiment [1] - The Shanghai Composite Index slightly increased by 0.09%, while the Shenzhen Component Index fell by 0.35%, and the pharmaceutical and biological sector dropped by 0.32%, reflecting a market shift towards defensive sectors [1] Capital Flow - On February 11, there was a net outflow of 512.31 million yuan in main funds, with large orders showing a net outflow of 533.39 million yuan, indicating a short-term reduction in institutional holdings [2] Trading Volume - The turnover rate was only 0.38% on that day, with a trading volume of 53.74 million yuan, down 25.8% from the previous day, suggesting low market participation [3] Financial Performance - In Q3 2025, the net profit attributable to the parent company decreased by 9.39% year-on-year, primarily due to a significant increase in R&D expenses by 36.20% [4] - The sales expense ratio rose by 4.19 percentage points to 31.86% year-on-year, with management and R&D expense ratios also increasing, which short-term eroded profits [4] Valuation - The current price-to-earnings ratio (TTM) is 77.65 times, which is higher than the average level of 40.66 times in the medical device sector, indicating valuation digestion pressure [5] Technical Analysis - The stock price has consecutively broken below the 20-day and 60-day moving averages, with a cumulative decline of 10.86% over the past 20 days, indicating a bearish technical pattern [6] Industry Policy - In November 2025, supportive policies for the medical device industry were announced in cities like Beijing and Shanghai, which are expected to benefit innovative device companies in the medium to long term [7] - The company reported a 30.58% year-on-year revenue growth in the first three quarters, with revenue from artificial biological heart valves increasing by 89.83%, and eight products in the pipeline entering the registration review stage [7] Future Outlook - The stock price hitting a 60-day low is mainly influenced by sector adjustments, capital outflows, and short-term performance pressures, but the company's product innovation and policy benefits provide a foundation for long-term development [8] - Attention should be paid to the effectiveness of future cost control and the progress of new product approvals [8]

Group 1 - The two major indices of the STAR Market opened slightly lower on January 27, but rebounded significantly after an initial drop, eventually closing with notable gains [1] - The STAR 50 Index closed at 1555.98 points, up 1.51%, with a total trading volume of approximately 102.1 billion yuan, showing a slight decrease compared to the previous trading day [1] - The STAR Composite Index closed at 1889.46 points, up 1.72%, with a total trading volume of about 324.5 billion yuan, also reflecting a slight decrease from the previous day [1] Group 2 - On January 27, 388 stocks in the STAR Market rose, accounting for approximately 64.77% of the total, with semiconductor stocks showing a strong upward trend [1] - In the performance of individual stocks, Shengke Communication and Dongxin Co., Ltd. reached a limit-up of about 20%, while Hexin Instruments saw a decline of 10.26%, marking the largest drop [2] - The average increase for the remaining 599 stocks, excluding suspended stocks, was 1.35%, with an average turnover rate of 3.93% and a total trading volume of 324.48 billion yuan [1]

Group 1 - The Sci-Tech Innovation 50 Index opened lower on January 23, followed by a narrow adjustment, and eventually closed with a slight increase of 0.78% at 1553.71 points, with a total trading volume of approximately 110.8 billion yuan [1] - The overall Sci-Tech Innovation Index rose by 1.85% to 1899.78 points, with a total trading volume of about 334.9 billion yuan [1] - On January 23, 600 stocks in the Sci-Tech Innovation Board saw an average increase of 2.28% and an average turnover rate of 3.87%, with a total trading volume of 334.9 billion yuan and an average fluctuation of 4.77% [1] Group 2 - In terms of individual stock performance, stocks such as Ruihua Technology, Laplace, Zhenlei Technology, and Jinko Solar reached their daily limit, showing significant gains [1] - Conversely, Jucheng Co. experienced a decline of 7.87%, marking the largest drop among the stocks [1] - In trading volume, Lanke Technology led with a total of 12.04 billion yuan, while ST Pava had the lowest trading volume at 1.258 million yuan [2] Group 3 - Regarding turnover rates, Aerospace Huanyu had the highest turnover rate at 22.28%, while Bairen Medical recorded the lowest at 0.18% [3]

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]